Ongoing Phase I Studies of Immune Checkpoint Inhibitors in China

WENFENG FANG,a,† SHEN ZHAO,a,c,† YAXIONG ZHANG,a,† YUXIANG MA,b HONGYUN ZHAO,b LI ZHANGa
Departments of aMedical Oncology and bClinical Research, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, People’s Republic of China; cZhongshan School of Medicine, Sun Yat-sen University, Guangzhou, People’s Republic of China
†Contributed equally.

Disclosures of potential conflicts of interest may be found at the end of this article.

Key Words. Phase I studies • Immune checkpoint inhibitors • Pharmacokinetics • Pharmacodynamics • China

ABSTRACT

Background. Cancer immunotherapy targeting immune checkpoint inhibitors (ICIs) has been shown to be a promising strategy in the treatment of various malignancies. Despite the proven efficacy and tolerability of ICIs based on 113 clinical trials globally, data regarding the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of ICIs in the Chinese population are lacking. As of June 1, 2018, not a single ICI has been approved by the China Food and Drug Administration.

Materials and Methods. Currently, there are 26 ongoing phase I studies actively investigating the safety, antitumor activity, and PK/PD profiles of six multinational corporation (MNC)-developed ICIs and eight domestic-developed ICIs in the Chinese population. Data regarding study designs, treatment interventions, targeted populations, and the current states of these studies were collected and summarized.

Results. We outlined 8 phase I studies assessing MNC-developed ICIs and 18 phase I studies assessing domestic-developed ICIs in the Chinese population in this article, in order to provide researchers with a clear picture of the status quo of ICI research and developments in China.

Conclusion. Immuno-oncology in China remains at a preliminary stage. Despite the substantial amount of phase I studies of ICIs, early-phase studies with designs incorporating characteristics of Chinese patients are still lacking.

Implications for Practice: Cancer immunotherapy targeting immune checkpoint inhibitors (ICIs) has led to a paradigm shift in the treatment of various malignancies. However, data regarding the pharmacokinetic and pharmacodynamic profiles of ICIs in the Chinese population are lacking. Currently, there are 26 phase I studies actively investigating 14 ICIs in China. In this article, we outlined all the ongoing phase I studies of multinational corporation-developed ICIs and domestic-developed ICIs targeting the Chinese population, hoping to shed some light on the status quo of ICI research and developments in China.
shown in 113 RCTs globally [2–13], not a single ICI has been approved by the China Food and Drug Administration (CFDA) as of the end of May 2018. In the era of immuno-oncology, China has lagged far behind its Western counterparts.

Fortunately, both the Chinese government and domestic biopharmas have realized this problem and are trying to close the gap between China and the West. By the end of November 2017, there are 10 domestic-developed ICIs being evaluated in phase I trials internationally and domestically. Another 11 domestic-developed ICIs are either in application for clinical trials or at preclinical stages (Table 1).

Altogether, there are 6 multinational corporation-developed (MNC-developed) ICIs and 8 domestic-developed ICIs being actively evaluated in 26 phase I studies in China (Table 2). Here, we outline all the ongoing phase I studies of ICIs in China, hoping to shed some light on the status quo of ICI research and development (R&D) in China and to identify challenges for future early-phase studies in the era of immuno-oncology.

MNC-Developed Agents

Anti-PD-1 Antibody

Nivolumab (Bristol-Myers Squibb; CheckMate077, NCT03195478, and CTR20171020)

Currently, there are three ongoing phase I studies of nivolumab among Chinese patients: CheckMate 077 (NCT02593786/CTR20150755), NCT03195478 (CTR20170731), and CTR 20171020.

CheckMate 077 is the first phase I study evaluating the safety, tolerability, PK profile, and preliminary antitumor activity of nivolumab monotherapy in Chinese patients. Compared with CA209-003 (NCT00730639) [17], the first-in-human study of nivolumab mostly including white patients, CheckMate 077 enrolled Chinese patients with advanced or metastatic nasopharyngeal carcinoma (NPC), lung cancer, hepatocellular carcinoma (HCC), and gastric cancer. Both studies excluded patients with chronic infections (e.g., human immunodeficiency virus [HIV] and hepatitis B virus [HBV] or C (HCV)) and patients with targetable driver mutations (e.g., epidermal growth factor receptor [EGFR] mutation, anaplastic lymphoma kinase [ALK] rearrangement). There is no requirement for tumor PD-L1 expression levels in both studies. Primary objectives of CheckMate 077 were the safety and tolerability of nivolumab in Chinese patients. Secondary objectives were PK/PD characteristics and preliminary antitumor activity.

Preliminary results of the first 15 patients were released at the 2017 Chinese Society of Clinical Oncology annual meeting [18]. Based on the released data, the safety and tolerability profiles of nivolumab in Chinese patients were similar to those of white patients. The most common treatment-related adverse events (TRAEs) were rash, decreased appetite, and fatigue. One patient discontinued treatment because of treatment-related serious (grade 3–4) adverse events, pancreatitis and cerebral hemorrhage. The most common immune-related adverse event (IRAE) was grade 1–2 skin events. Grade 3 adverse events (AEs) were seen in three patients; no grade 4 AE or death was observed.

PK parameters of nivolumab among Chinese patients were also comparable to those of white patients [17]. However, the Tmax (median time of maximum serum concentration, hours)

| Table 1. The development of all domestic ICIs |
|---------------------------------------------|
| ICI | Company | Stage of development |
| PD-1 inhibitor | SHR1210 | Jiangsu HengRui Medicine Co. Ltd. | Phase III RCT |
| | BGB-A317 | BeiGene Co. Ltd. | Phase III RCT |
| | IBI-308 | Innovent Biologics (Suzhou) Co. Ltd. | Phase III RCT |
| | JS001 | Shanghai Junshi Bioscience Co. Ltd. | Phase II RCT |
| | GLS-010 | Harbin Junshi Pharmaceutical Co. Ltd. and WuXi AppTec Co. Ltd. | Phase I RCT |
| | CBT-501/GB226 | CBT Pharmaceuticals, Inc. | Phase I RCT |
| | BAT1306 | Bio-Thera Solutions, Ltd | Approve for RCT |
| | AK103 | Akeso Biopharma, Inc. | Approve for RCT |
| | LZM009 | Livzon Pharmaceutical Group Inc. | IND (37) |
| | HLX10 | Shanghai Henlius Biotech, Inc. | IND (103) |
| | AK105 | Akeso Biopharma, Inc. | Preclinical |
| | SSI-361 | Anhui Anke Biotechnology (Group) Co., Ltd. | Preclinical |
| PD-1/CTLA-4 co-inhibitor | AK104 | Akeso Biopharma, Inc. | Phase I RCT |
| PD-L1 inhibitor | KN035 | 3D Medicines (Sichuan) Co. Ltd. | Phase I RCT |
| | CS1001 | CStone Pharmaceuticals Co. Ltd. | Phase I RCT |
| | SHR1316/HTI-1088 | Jiangsu HengRui Medicine Co. Ltd. | Phase I RCT |
| | STI-A1014 | Lee’s Pharmaceutical Holdings Limited | IND (55) |
| | KL-A167 | Sichuan Kelun Pharmaceutical Co., Ltd. | IND (35) |
| | TQB2450 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | IND (51) |
| | AK106 | Akeso Biopharma, Inc. | Preclinical |
| | HLX09 | Shanghai Henlius Biotech, Inc. | Preclinical |

Abbreviations: CTLA-4, cytotoxic T-lymphocyte-associated protein 4; ICI, immune checkpoint inhibitor; IND, investigation new drug (the drug has finished preclinical stage but has not been approved by the China Food and Drug Administration for clinical trials); PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; RCT, randomized controlled trial.
Table 2. Ongoing phase I studies of immune checkpoint inhibitors conducted in China

| No. | Agents | Identifiers | Locations | Tumor types[^a] | Enrollment | Launched date | Current status |
|-----|--------|-------------|-----------|-----------------|------------|--------------|---------------|
|     |        |             |           |                 |            |              |               |
| International agents | | | | | | | |
| 1   | Nivolumab | NCT02593786 CheckMate077 CTR20150755 | Guangzhou, China | NPC, NSCLC, SCLC, HCC, CRC, gastric cancer | 56 | 12/25/2015 | Recruiting |
| 2   | Nivolumab | CTR20171020 | China; Thailand | NSCLC | 400[^b] | 9/25/2017 | Recruiting |
| 3   | Pembroliuzumab | NCT02835690 KEYNOTE032 | Beijing, China | NSCLC | 42 | 8/4/2016 | Ongoing, not recruiting |
| 4   | Atezolizumab/atezolizumab+gemcitabine-cisplatin | NCT02825940 IMYO29233 | Beijing, China; Guangzhou, China; Harbin, China; Shanghai, China | Solid tumors | 120[^c] | 8/4/2016 | Recruiting |
| 5   | Durvalumab/durvalumab+tremelimumab | NCT02978482 | Beijing, China; Changchun, China | Solid tumors other than HCC | 26 | 12/1/2016 | Ongoing, not recruiting |
| 6   | Avelumab | CTR20171035 | Beijing, China | Dose escalation: solid tumors; Dose expansion: esophageal squamous cell carcinoma | 74 | 11/10/2017 | Recruiting |
| 7   | Ipilimumab | NCT02516527 | Guangzhou, China | Malignant melanoma | 36 | 10/16/2015 | Recruiting |
| 8   | Nivolumab + ipilimumab | NCT03195478 CTR20170731 | Beijing, China | Solid tumors | 27 | 7/27/2017 | Recruiting |
|     |        |             |           |                 |            |              |               |
| Domestic agents | | | | | | | |
| 1   | SHR1210 | NCT02742935 | Guangzhou, China | Breast cancer, gastrointestinal cancer | 96 | 4/1/2016 | Enrolling participant (by invitation only) |
| 2   | SHR1210 | NCT02738489 | Guangzhou, China | Malignant melanoma | 36 | 4/1/2016 | Enrolling participant (by invitation only) |
| 3   | SHR1210 | NCT02721589 | Guangzhou, China | Lung cancer | 45 | 4/1/2016 | Enrolling participant (by invitation only) |
| 4   | SHR1210 | CTR20160175 | Guangzhou, China | Solid tumors, especially lung cancer, NPC, esophageal carcinoma, gastric carcinoma, and HCC | 32–51 | 3/30/2016 | Recruiting |
| 5   | JS001 | NCT02857166 \ CTR20160176 | Guangzhou, China | Adenocarcinoma of solid tumor | 24 | 3/1/2016 | Ongoing, not recruiting |
| 6   | JS001 | NCT02836834 CTR20160274 | Beijing, China | Lung cancer, lymphoma | 90 | 8/1/2016 | Recruiting |
| 7   | JS001 | NCT02836795 \ CTR20160187 | Beijing, China | Malignant melanoma, urological cancer | 35 | 4/1/2016 | Ongoing, not recruiting |
| 8   | JS001 | NCT02838823 CTR20160412 | Beijing, China | TNBC | 27 | 7/1/2016 | Recruiting |
| 9   | JS001 + axitinib | NCT03086174 CTR20170109 | Beijing, China | Kidney cancer, malignant melanoma | 24 | 3/31/2017 | Recruiting |
| 10  | JS001 + gemcitabine-cisplatin | NCT03251313 \ CTR20160813 | Shanghai, China | TNBC | 33 | 11/1/2017 | Not yet open for recruitment |
| 11  | JS001 + radiotherapy | CTR20160976 | Shanghai, China | TNBC | 54 | 12/9/2016 | Not yet open for recruitment |

(continued)
The CTR20171020 study is an international, multicenter, single-arm study investigating the safety and tolerability of nivolumab monotherapy in Asian patients with refractory/metastatic non-small cell lung cancer (NSCLC). Chinese hospitals account for 80% of the centers (24/28), and Lu S. from Shanghai Chest Hospital is the global principal investigator of the study. Patients carrying positive EGFR mutations or ALK rearrangements who were refractory or recurrent to the first-line target therapy are eligible. Patients who tested positive for HBV infection but had HBV DNA ≤500 IU/mL can also be enrolled. Patients are excluded if they failed to be enrolled into any other PD-1/PD-L1 study solely because of low or negative predictive biomarkers. The study enrolled its first domestic patient on the September 30, 2017, and is currently recruiting participants domestically and globally. Instead of simply copying the design of foreign trials, the first study considering characteristics of Asian patients. By including EGFR-mutant NSCLC and patients with chronic, inactive HBV infections, its results are definitely worth expecting.

**Pembrolizumab (Merck & Co.; KEYNOTE 032)**

The KEYNOTE 032 (NCT02835690/MK-3475-032) study is a randomized dose-escalation phase I study targeting Chinese patients with advanced NSCLC. The dose-escalation scheme is 2 mg/kg, 10 mg/kg, and 200 mg once every three

---

**Table 2. (continued)**

| No. | Agents | Identifiers | Locations | Tumor typesa | Enrollment | Launched date | Current status |
|-----|--------|-------------|-----------|--------------|------------|---------------|---------------|
| 12  | BGB-A317 | CTR20160872 | Guangzhou, China; Beijing, China; Harbin, China; Hangzhou, China; Shanghai, China; Nanjing, China | Solid tumors | 240b | 12/19/2016 | Recruiting |
| 13  | IBI-308 | NCT02937116 CTR20160735 | Beijing, China; Guangzhou, China | Solid tumors | 104a | 10/1/2016 | Ongoing, not recruiting |
| 14  | GLS-010 | CTR20170433 | Beijing, China | Solid tumors, especially gastric carcinoma, esophageal carcinoma | 84 | 5/18/2017 | Recruiting |
| 15  | GLS-010 | CTR20170692 | Beijing, China | Solid tumors, especially TNBC, HCC | 84 | 7/27/2017 | Not yet open for recruitment |
| 16  | CBT-501/GB226 | CTR20170262 | Beijing, China; Changsha, China; Harbin, China | Solid tumors, lymphomas | 72 | 7/24/2017 | Not yet open for recruitment |
| 17  | KN035 | NCT03310488 CTR20170036 | Beijing, China | Solid tumors | 14–36 | 3/21/2017 | Recruiting |
| 18  | CS1001 | NCT03312842 CTR20170916 | Beijing, China; Shanghai, China | Solid tumors, lymphomas | 300c | 9/6/2017 | Not yet open for recruitment |

*All are advanced or metastatic tumors refractory or recurrent or intolerant to any available effective standard therapy.*

bCTR20171020 is a single-arm study investigating nivolumab in Asian patients with refractory/metastatic NSCLC. It plans to enroll 400 patients to fully investigate grade 3–5 adverse events, which usually have low occurrence rates.

bCTR20160872 is a single-arm, phase I/II study that aims to investigate the safety, PK/PD profiles, and preliminary antitumor activity of BGB-A317 in Chinese patients.

bCTR20171020 is the first domestic patient on the September 30, 2017, and is currently recruiting participants domestically and globally.
weeks for 35 administrations or until disease progression or unacceptable toxicity. Cycle 1 is 28 days instead of 21 days. Primary objectives are safety, tolerability, and PK profile of pembrolizumab monotherapy. The study was launched on the August 4, 2016, and is currently recruiting participants.

Anti-PD-L1 Antibody

Atezolizumab (F Hoffmann-La Roche/Genentech Inc.; IMYO29233)

The IMYO29233 (NCT02825940) study is a phase I study investigating the PK profile, safety, and preliminary antitumor activity of atezolizumab monotherapy and atezolizumab plus chemotherapy in Chinese patients with advanced solid tumors. Patients in the monotherapy cohort receive atezolizumab 1,200 mg intravenously once every 3 weeks until confirmed disease progression or unacceptable toxicity. Patients with treatment-naïve stage IV NSCLC are enrolled in the combination cohort and receive atezolizumab (1,200 mg) on Day 1 combined with gemcitabine (1,250 mg/m²) on Days 1 and 8 plus cisplatin (75 mg/m²) on Day 1 of a 21-day cycle. The cycle will repeat four or six times at the discretion of investigators, followed by atezolizumab (1,200 mg) alone once every 3 weeks. There is no requirement for tumor PD-L1 expression levels in the monotherapy cohort, but patients enrolled into the combination cohort must have positive PD-L1 expression (PD-L1 expressed by ≥1% of the tumor cells). Primary outcomes are safety, tolerability, and PK profiles of atezolizumab monotherapy and atezolizumab plus chemotherapy in Chinese patients. The study is recruiting participants and is estimated to be completed by July 10, 2020.

Durvalumab (AstraZeneca; NCT02978482)

The study, tolerability, and antitumor activity of durvalumab (MED14736) was first assessed and confirmed in the NCT01693562 study. The PK/PD profile and feasibility of durvalumab in combination with tremelimumab, a CTLA-4 inhibitor, are now being evaluated in three phase I studies (NCT02262741, NCT01975831, and NCT02978482). The completed NCT02262741 study targeted recurrent/metastatic head and neck squamous cell carcinomas with positive PD-L1 expression (PD-L1 expressed by ≥1% of the tumor cells), whereas the ongoing NCT01975831 study in the U.S. and NCT02978482 study in China target patients with advanced/metastatic solid tumors, regardless of tumor PD-L1 expression levels.

The NCT02978482 study consists of two cohorts. Participants in the monotherapy cohort are treated with durvalumab 20 mg/kg every 4 weeks until disease progression or unacceptable toxicity, whereas participants in the durvalumab + tremelimumab cohort receive durvalumab 20 mg/kg every 4 weeks plus tremelimumab 1 mg/kg once every 4 weeks for four cycles, followed by durvalumab (20 mg/kg every 4 weeks) alone. The primary outcomes include PK parameters and safety data. The study was completed on November 15, 2018, but results have not been published yet.

Avelumab (Merck KGaA and Pfizer; CTR20171035)

Avelumab is the latest ICI approved by the U.S. FDA for the treatment of metastatic Merkel cell carcinoma and refractory, locally advanced, or metastatic urothelial carcinoma. The CTR20171035 study is the first domestic study of avelumab that aims to characterize the PK/PD profiles of avelumab monotherapy in Chinese patients. The study consists of a dose-escalation phase and a dose-expansion phase, the latter of which targets patients with advanced esophageal squamous cell carcinoma (ESCC). Patients are enrolled regardless of tumor PD-L1 expression levels. Patients tested positive for HIV, HBV, or HCV infections are ineligible. Participants will be treated with avelumab 10 mg/kg intravenously once every 2 weeks until disease progression or unacceptable toxicity. The primary outcomes include DLT, PK data, and preliminary antitumor activity. The study first released information on November 10, 2017, and is currently recruiting participants.

Anti-CTLA-4 Antibody

Ipilimumab (Bristol-Myers Squibb; NCT02516527 and NCT03195478)

The NCT02516527 study is a randomized, open-label, dose-escalation phase I study investigating ipilimumab monotherapy in Chinese patients. Patients with advanced or metastatic malignant melanoma regardless of tumor PD-L1 expressions are eligible. Participants are treated with ipilimumab 3 mg/kg or 10 mg/kg intravenously once every 3 weeks for four cycles, followed by ipilimumab monotherapy (3 mg/kg or 10 mg/kg) every 12 weeks until either 3 years, disease progression, or unacceptable toxicity. The primary objective is to assess the safety and tolerability of ipilimumab monotherapy and to determine the DLT and MTD. Secondary objectives are the PK profile and preliminary antitumor activity. The study was launched on October 16, 2015, and is estimated to be completed on November 26, 2019.

The safety, tolerability, PK profile, and efficacy of ipilimumab plus nivolumab in Chinese patients with pretreated advanced or recurrent solid tumors are being assessed in the NCT03195478 study as mentioned above.

DOMESTIC-DEVELOPED AGENTS

Anti-PD-1 Antibody

SHR1210 (Jiangsu HengRui Medicine Co. Ltd.; NCT02742935, NCT02738489, NCT02721589, and CTR20160175)

SHR1210 is the first ICI independently developed by Chinese biopharmas. Its new drug application (NDA) had been submitted to the Chinese Center for Drug Evaluation (CDE) on April 19, 2018, using Hodgkin lymphoma as the lead indication.

Currently, there are four ongoing phase I trials assessing the safety and tolerability of SHR1210 monotherapy in Chinese patients. The CTR20160175 study is a dose-escalation study that evaluates SHR-1210 monotherapy in Chinese patients with advanced or metastatic solid tumors (particularly focusing on lung cancer, NPC, esophageal carcinoma, gastric
carcinoma, and HCC). The dose-escalation scheme is 1 mg/kg, 3 mg/kg, 10 mg/kg, and 200 mg on Day 1 of the first 28 days, followed by unchanged dosages of SHR-1210 every 2 weeks. Safety and tolerability are the primary outcomes. Secondary outcomes include PK parameters, immunogenicity, and preliminary antitumor activity. The study enrolled its first patient on April 6, 2016, and is currently recruiting participants. NCT02742935, NCT02738489, and NCT02721589 target patients with refractory advanced or metastatic breast cancer/gastrointestinal cancer (NCT02742935), malignant melanoma (NCT02738489), and lung cancer (NCT02721589), respectively.

According to the latest released results of NCT02742935 [19, 20], treatment with SHR1210 in advanced/refractory ESCC resulted in an objective response rate of 33.3% and a median progression-free survival of 3.6 months. The most common TRAEs were reactive capillary hemangiomas (76.7%, 23/30), which was believed to be related to the activation of vascular endothelial growth factor (VEGF)/VEGF receptor pathway. In the intense market competition of ICIs, this adverse event, although not life-threatening, may be a flaw for SHR1210. Jiangsu HengRui is now actively dealing with this problem by combining SHR1210 with chemotherapy or antiangiogenic agents.

**JS001 (Shanghai Junshi Bioscience Co. Ltd.; NCT02857166, NCT02836834, NCT02836795, NCT02838823, NCT03086174, NCT03251313, and CTR20160976)**

JS001 is the first domestic-developed ICI granted clinical trial approval by the CFDA. On March 9, 2018, Chinese CDE formally accepted its NDA, with melanoma as the lead indication. Preclinical study of JS001 found that it could specifically bind to PD-1 antigen with an EC$_{50}$ of 21 nmol/L, and could competently block the binding of PD-1 antigen to PD-L1 and PD-L2 with IC$_{50}$ of 3.0 and 3.1 nmol/L, respectively [21].

Currently, there are five phase I studies evaluating JS001 monotherapy in Chinese patients with various malignancies. The NCT02857166 (CTR20160176) study was the first-in-human study of JS001 recruiting patients with adenocarcinoma of the stomach or gastroesophageal junction, ESCC, NPC, cholangiocarcinoma, and pancreatic ductal cell carcinoma. It adopted the classic 3 + 3 dose escalation design and contained a dose expansion cohort using a fixed-dose of 240 mg once every 2 weeks. There was no restriction on patients’ PD-L1 expression levels. Preliminary study results were released at the 2017 European Society for Medical Oncology annual meeting (1186P). A total of 25 patients were included. No DLT or MTD was identified. The elimination half-life ranged between 6 and 15 days. Among 13 evaluable patients, 1 patient with melanoma achieved confirmed complete remission, 2 achieved confirmed partial remission, and 2 achieved stable disease.

The NCT02836834 (CTR20160274), NCT02836795 (CTR20160187), and NCT02838823 (CTR20160412) studies are all single-center dose-escalation studies evaluating the tolerability and PK profile of JS001 in patients with refractory advanced or metastatic lung cancer/lymphoma (NCT02836834), malignant melanoma/urological cancer (NCT02836795), and triple-negative breast cancer (TNBC; NCT02838823), regardless of their PD-L1 expression levels. These studies all adopted identical dose-escalation schemes. Planned dosage levels are 1 mg/kg, 3 mg/kg, and 10 mg/kg intravenously once every 2 weeks until disease progression or unacceptable toxicity. Their primary objectives are to assess the safety, tolerability, DLT, and MTD of JS001 monotherapy. All studies were launched in 2016 and are currently recruiting participants.

The possibility of combining JS001 with other treatment modalities for advanced or metastatic solid tumors is also under investigation. The NCT03086174 (CTR20170109) study is a dose-escalation phase Ib study evaluating the safety, tolerability, and PK profile of JS001 plus axitinib in Chinese patients with refractory stage IV kidney cancer and advanced melanoma. The NCT03251313 (CTR20160813) study and the CTR20160976 study both target patients with refractory advanced or metastatic TNBC. The NCT03251313 study investigates the tolerability and PK profiles of JS001 plus gemcitabine-cisplatin, and the CTR20160976 study evaluates the feasibility of JS001 in combination with radiotherapy. All these studies were launched in 2017.

**BGB-A317 (BeiGene Co. Ltd.; NCT02407990, CTR20160872, NCT02795182, and NCT02660034)**

BGB-A317 is a novel anti-PD-1 antibody designed and developed independently by BeiGene, a rising star of the Chinese anticancer drug R&D. It is distinguished from the currently approved PD-1 antibodies with its inability to bind to Fcγ receptor I (FcγRI/CD64) and its unique binding signature to PD-1, both of which granted BGB-A317 high affinity and superior specificity toward PD-1 [22].

Two phase I studies (NCT02407990 and CTR20160872) evaluating BGB-A317 monotherapy are recruiting participants from international and domestic centers, respectively. The CTR20160872 study is a domestic, multicenter phase I study that aims to investigate the safety, PK/PD data, antitumor activity, MTD, and the recommended phase II dose of BGB-A317 for Chinese patients with refractory advanced or metastatic solid tumors. Patients are excluded if they failed to be enrolled into other PD-1/PD-L1 trials solely because of low or negative predictive biomarkers. It includes a dose-escalation section and a dose expansion section. The dose-escalation section adopts a modified 3 + 3 design to determine the DLT and MTD of BGB-A317 monotherapy. The dose expansion section divides participants based on their tumor types to further assess the antitumor activity of BGB-A317 in different malignancies. The study enrolled its first patient on December 28, 2016.

The feasibility of BGB-A317 in combination with other novel agents in the treatment of advanced cancers is also being explored. The NCT02795182 study, a multicenter phase Ib study in Australia, assesses the combination of BGB-A317 and BGB-3111, a Bruton’s tyrosine kinase inhibitor, in patients with B-cell malignancies. The NCT02660034 study, another multicenter phase Ib study in Australia, investigates BGB-A317 in combination with BGB-290, a selective poly ADP-ribose polymerase inhibitor, in patients with advanced solid tumors. Both studies were started in 2016 and are recruiting participants.
The CTR20170433 study enrolled its 1 mg/kg, 4 mg/kg, 10 mg/kg, and 240 mg once every 4 weeks. Preclinical data suggests that these dosage levels are safe and well-tolerated. The planned dose levels are 1 mg/kg, 3 mg/kg, 10 mg/kg, and 200 mg, once every 3 weeks) adopting the classic 3 + 3 dose-escalation scheme. Phase Ib evaluates the tolerability and antitumor activity of IBI308 monotherapy (200 mg once every 3 weeks) in patients with malignant melanoma (Cohort A), gastrointestinal carcinoma (Cohort B), and NSCLC (Cohort C), as well as the feasibility of IBI308 in combination with chemotherapy in treatment-naive advanced nonsquamous NSCLC without targetable driver mutations (e.g., EGFR mutations or ALK rearrangement; Cohort D), squamous NSCLC (Cohort E), and adenocarcinoma of the stomach or gastroesophageal junction (Cohort F). Patients previously exposed to PD-1/PD-1 inhibitors are excluded. Patients previously treated with anti-CTLA-4 antibodies are eligible if they show full resolution of IRAEs, no history of grade 4 IRAEs, a minimum of a 12-week interval from the first dose of the anti-CTLA-4 antibody, and a minimum of a 6-week interval from the last dose. Patients who have unequivocal disease progression after one dose of the anti-CTLA-4 antibody can also be considered for enrollment. The primary outcomes are safety and preliminary antitumor activity. Secondary outcomes are PK parameters. The study was launched in October 2016. It has finished recruitment in 2017, but no results have been published yet.

GLS-010 (Harbin Gloria Pharmaceutical Co. Ltd. and WuXi AppTec Co. Ltd.; NCT20170433 and CTR20170692) GLS-010 is a PD-1 inhibitor codeveloped by Chinese and American biopharmas. Two multicenter phase I studies (CTR20170433 and CTR20170692) are ongoing to evaluate the safety, tolerability, preliminary antitumor activity, and PK profile of GLS-010 monotherapy in Chinese patients. The CTR20170433 study targets patients with gastric carcinoma and esophageal carcinoma, whereas the CTR20170692 study targets TNBC and HCC. Non-HCC patients with HBV or HCV infection and HCC patients with HBV and HCV coinfection are precluded from enrollment. The planned dose levels are 1 mg/kg, 4 mg/kg, 10 mg/kg, and 240 mg once every 4 weeks. The CTR20170433 study enrolled its first patient in China on July 13, 2017; the CTR20170692 study is not yet open for recruitment.

CBT-501/GB226 (CBT Pharmaceuticals, Inc.; NCT03053466 and CTR20170262) In preclinical studies, CBT-501 showed comparable efficacy profile to nivolumab and pembrolizumab both in vitro and in vivo. Also, CBT Pharmaceuticals claimed that CBT-501 had lower undesirable antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity. However, no clinical data of CBT-501 are available yet.

The CTR20170262 study is a domestic, multicenter phase I trial targeting advanced or recurrent solid tumor and lymphoma patients in China. Patients previously treated with PD-1/PD-L1/PD-L2 or CTLA-4 inhibitors are ineligible. Participants assigned to three cohorts are treated with three planned dose levels (1 mg/kg, 3 mg/kg, 10 mg/kg) on Day 1 and Day 15 of a 28-day cycle. The NCT03053466 study is a multicenter dose-escalation study conducted in Australia with identical designs. The primary objectives of both studies are to assess the safety and tolerability of CBT-501. Secondary objectives are the PK profile and preliminary efficacy.

Anti-PD-L1 Antibody

KN035 (3D Medicines [Sichuan] Co. Ltd.; NCT03101488, NCT02827968, and NCT03248843) KN035 is a PD-L1 inhibitor that adopts a different method of administration. Instead of being given intravenously, it is injected subcutaneously. The safety and PK profile of KN035 monotherapy in patients with advanced or metastatic solid tumors are under investigation in three dose-escalation phase I studies in China (NCT03101488 [CTR20170036]), the U.S. (NCT02827968), and Japan (NCT03248843), respectively. The inclusion and exclusion criteria are identical among the three studies. Patients are considered for enrollment regardless of their PD-L1 expression levels. Patients previously exposed to PD-1 or PD-L1 antibodies are excluded. Patients previously treated with ipilimumab can be enrolled if they show full resolution of IRAEs, no history of grade 4 IRAEs, a minimum of a 12-week interval from the first dose of ipilimumab, and a minimum of a 6-week interval from the last dose. Patients who have unequivocal disease progression after one dose of ipilimumab are enrolled if they show full resolution of IRAEs, no history of grade 4 IRAEs, a minimum of a 12-week interval from the first dose of ipilimumab, and a minimum of a 6-week interval from the last dose, or have unequivocal disease progression after one dose of ipilimumab. The primary objectives are safety and tolerability assessed by TRAEs and DLT. The secondary outcomes are PK and PD parameters. The studies in China and the U.S. are recruiting participants; the study in Japan is not open for recruitment yet.

CS1001 (CStone Pharmaceuticals Co. Ltd.; NCT03312842) CS1001, a fully human, full-length anti-PD-L1 antibody developed by the Open Monoclonal Technology Inc. transgenic animal platform, mirrors natural human immunoglobulin G4 and therefore can reduce the risk of immunogenicity and potential toxicity in patients. The NCT03312842 (CTR20170916) study is a domestic, phase Ia/Ib, open-label study evaluating the safety, tolerability, PK profile, and antitumor activity of CS1001 in Chinese patients with advanced malignancies. The study consists of a dose-escalation part and an expansion part. The dose-escalation part adopts a modified 3 + 3 design. Planned dose levels are 3 mg/kg, 10 mg/kg, 20 mg/kg, 40 mg/kg, and 1,200 mg fixed dose once every 3 weeks until disease progression or unacceptable toxicity. Primary outcomes are safety and tolerability assessed by AEs, DLT, and MTD. Secondary outcomes are PK parameters and immunogenicity. The study is currently
DISCUSSION

To date, a total of six MNC-developed ICIs and eight domestic-developed ICIs are being evaluated in 26 different phase I studies (Fig. 1). The majority of ongoing phase I studies in China investigate the safety, tolerability, and PK/PD profile of ICI monotherapy, whereas the remaining studies assess the feasibility of combining ICIs with other treatment modalities, attempting to provide new strategies for the treatment of advanced malignancies.

For MNC-developed agents, all the approved ICIs have shown promising efficacy and tolerability in various malignancies in large-scale RCTs. However, it remains unclear whether these agents are equally safe and effective among Chinese patients. According to the results of CheckMate 077, the safety, tolerability, and PK/PD profile of nivolumab monotherapy in Chinese NSCLC and NPC patients were generally comparable to those of white patients [17]. Although the PK data were slightly different between the two populations, it is still unknown whether these discrepancies are clinically relevant. Future studies of MNC-developed ICIs specified for Chinese patients are needed to verify the tolerability and efficacy of these agents in the Chinese population.

As for the domestic-developed agents, despite the rapid development of domestic-developed ICIs in China, we are still far behind our international counterparts in the field of immuno-oncology. Here, we identified some problems that are worth further consideration in future clinical and preclinical studies. First, the absence of a reliable predictive biomarker for the efficacy of PD-1/PD-L1 inhibitors has led to inconsistent inclusion criteria in clinical trials. Some studies only enrolled patients with positive PD-L1 expression status (PD-L1 expressed at ≥1% of tumor cells), whereas other studies enrolled patients regardless of PD-L1 expression levels. This is a common problem shared by international and domestic trials, which may result in a potential bias of phase I studies. Second, the inclusion and exclusion criteria of current phase I studies in Chinese patients fail to incorporate characteristics of the Chinese population. Despite of the heavy burden of HBV infection in China [23], only one study (CTR20171020) enrolls patients who test positive for HBV infections. The majority of current phase I studies elect to exclude patients with chronic HBV or HCV infections. Although it is understandable that excluding patients with chronic infections may reduce the risk of TRAEs and guarantee the safety and tolerability of the tested agent, it is still unknown whether it’s necessary and scientifically solid to exclude all patients who test positive for HBV/HCV infections from ICI treatments regardless of their viral load. Moreover, the relationship between HBV infection and the efficacy and tolerability of ICIs also warrants further investigation. It was reported by Lin et al. that the expression of PD-L1 in NSCLC was increased in patients with chronic hepatitis B [24]. Therefore, additional phase I studies or phase IV studies assessing the safety, tolerability, and efficacy of ICIs in HBV/HCV-positive cancer patients are urgently needed.

With the rapid development of novel agents and treatment strategies, phase I studies in the immuno-oncology

![Figure 1](http://theoncologist.alphamedpress.org/Downloaded-from-April-28-2019)
era have evolved from simple safety and PK/PD investigations to proof-of-concept or proof-of-mechanism studies that assess antitumor activities [25]. The “seamless drug development strategy” now becomes the trend that more and more phase I studies progress from a first-in-human study to expansion phase that can be used to directly support drug registration. However, among the 26 phase I studies in China, only 12 consist of dose expansion phases that aim to investigate preliminary antitumor activities. Only five studies plan to explore prognostic biomarkers for immunotherapy. And several domestic-developed ICIs are investigated in multiple studies with different indications but identical designs. Undoubtedly, conducting early-phase oncology trials in China may be beneficial because of their lower cost of operations and large patient populations [26]. However, these advantages could be easily offset by the lack of patient enrichment strategies or inefficient study designs. In this sense, China still has a long way to go.

CONCLUSION

Cancer immunotherapy is a newly emerging and ever-changing field of current cancer treatment. ICI monotherapy has led to paradigm shifts in the treatment for various malignancies. Combining ICIs with other treatment modalities is also gradually becoming the focus of future studies. Immuno-oncology in China remains at a preliminary stage. Phase I studies exploring the safety, antitumor activity, and PK/PD profiles of ICIs in Chinese patients are essential foundations for selecting clinical drug delivery modes and planning future large-scale phase II/III RCTs of immunotherapy in the Chinese population.

ACKNOWLEDGMENTS

This work was supported by National Key R&D Program of China (Grant No. 2016YFC0905500, 2016YFC0905503), Science and Technology Program of Guangdong (Grant No. 2017B020227001, Grant No. 2016A020215084), Science and Technology Program of Guangzhou (Grant No. 201607020031, Grant No. 201400000001-2), Chinese National Natural Science Foundation Project (Grant No. 81772476, Grant No. 81572659, Grant No. 81602011), Pearl River Nova Program of Guangzhou (Grant No. 201610010048), and National Natural Science Funds for Young Scholars of China (Grant No. 81502355).

AUTHOR CONTRIBUTIONS

Conception/design: Wenfeng Fang, Shen Zhao, Yaxiong Zhang, Yuxiang Ma, Hongyun Zhao, Li Zhang

Manuscript writing: Wenfeng Fang, Shen Zhao, Yaxiong Zhang, Yuxiang Ma, Hongyun Zhao, Li Zhang

Final approval of manuscript: Wenfeng Fang, Shen Zhao, Yaxiong Zhang, Yuxiang Ma, Hongyun Zhao, Li Zhang

DISCLOSURES

The authors indicated no financial conflicts of interest.

REFERENCES

1. Burugu S, Danscoo AR, Nielsen TO. Emerging targets in cancer immunotherapy. Semin Cancer Biol 2018;52:39–52.
2. Balar AV, Galsky MD, Rosenberg JE et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: A single-arm, multicentre, phase 2 trial. Lancet 2017;389:67–76.
3. Beer TM, Kwon ED, Drake CG et al. Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naïve castration-resistant prostate cancer. J Clin Oncol 2017;35:40–47.
4. El-Khoueiry AB, Sangro B, Yau T et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017;389:2492–2502.
5. Ferris RL, Blumenschein G Jr, Fayette J et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 2016;375:1856–1867.
6. Garon EB, Rizvi NA, Hui R et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015;372:2018–2028.
7. McDermott DF, Sosman JA, Sznol M et al. Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: Long-term safety, clinical activity, and immune correlates from a phase Ia study. J Clin Oncol 2016;34:833–842.
8. Overman MJ, McDermott R, Leach JL et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): An open-label, multicentre, phase 2 study. Lancet Oncol 2017;18:1182–1191.
9. Peters S, Gettinger S, Johnson ML et al. Phase II trial of atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand 1-selected advanced non-small-cell lung cancer (BIRCH). J Clin Oncol 2017;35:2781–2789.
10. Powles T, Eder JP, Fine GD et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014;515:558–562.
11. Rosenberg JE, Hoffman-Censits J, Powles T et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial. Lancet 2016;387:1909–1920.
12. Sharma P, Callahan MK, Bono P et al. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): A multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet Oncol 2016;17:1590–1598.
13. Weber J, Gilbey G, Kudchadkar R et al. Phase I/II study of metastatic melanoma patients treated with nivolumab who had progressed after ipilimumab. Cancer Immunol Res 2016;4:345–353.
14. Lipson EJ, Drake CG. Ipilimumab: An anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res 2011;17:6958–6962.
15. Barone A, Hazarika M, Theoret MR et al. FDA approval summary: Pembrolizumab for the treatment of patients with unresectable or metastatic melanoma. Clin Cancer Res 2017;23:5661–5665.
16. Beaver JA, Theoret MR, Mushit S et al. FDA approval of nivolumab for the first-line treatment of patients with BRAFV600 wild-type unresectable or metastatic melanoma. Clin Cancer Res 2017;23:3479–3483.
17. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443–2454.
18. Zhang L, Fang W, Zhang Y et al. Preliminary safety and pharmacokinetic results from a phase 1/2 study of Nivolumab in previously treated Chinese patients with advanced or recurrent solid tumors (CheckMate 077 cohort A). Poster presented at: 20th Annual Meeting of the Chinese Society of Clinical Oncology, Xiamen, China; 2017.
19. Huang J, Xu B, Mo H et al. Safety, activity, and biomarkers of SHR-1210, an anti-PD-1 antibody, for patients with advanced esophageal carcinoma. Clin Cancer Res 2018;24:1296–1304.
20. Mo H, Huang J, Xu J et al. Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: A dose-escalation, phase 1 study. Br J Cancer 2018;119:538–545.

www.TheOncologist.com © AlphaMed Press 2019
21. Fu J, Wang F, Dong LH et al. Preclinical evaluation of the efficacy, pharmacokinetics and immunogenicity of JS-001, a programmed cell death protein-1 (PD-1) monoclonal antibody. Acta Pharmacol Sin 2017;38:710–718.

22. Zhang T, Song X, Xu L et al. The binding of an anti-PD-1 antibody to FγRIIA has a profound impact on its biological functions. Cancer Immunol Immunother 2018;67:1079–1090.

23. Wang FS, Fan JG, Zhang Z et al. The global burden of liver disease: The major impact of China. Hepatology 2014;60:2099–2108.

24. Lin G, Zhuang W, Chen XH et al. Increase of programmed death ligand 1 in non-small cell lung cancers with chronic hepatitis B. Ann Oncol 2018;29:516–517.

25. Kummar S. The evolving paradigm of cancer trials. Nat Rev Drug Discov 2018;17:225–226.

26. Mullard A. Chinese biopharma starts feeding the global pipeline. Nat Rev Drug Discov 2017;16:443–446.